Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00072007|
Recruitment Status : Completed
First Posted : November 6, 2003
Last Update Posted : May 15, 2012
RATIONALE: Drugs used in chemotherapy, such as cladribine, use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining cladribine with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving cladribine and rituximab as remission induction therapy together with rituximab and stem cell mobilization in treating patients with chronic lymphocytic leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: filgrastim Biological: rituximab Drug: CHOP regimen Drug: cladribine Drug: cyclophosphamide Drug: doxorubicin hydrochloride Drug: prednisone Drug: vincristine sulfate||Phase 2|
- Determine the efficacy and tolerability of cladribine and rituximab as remission induction therapy in patients with chronic lymphocytic leukemia.
- Determine the complete remission rate in patients treated with this regimen.
- Determine the very good partial remission rate and nodular partial remission rate in patients treated with this regimen.
- Determine the toxicity of this regimen, in terms of hemotoxicity and infection rate, in these patients.
- Determine the efficacy of in vivo purging with rituximab measured by immunophenotyping in these patients.
- Determine the feasibility of stem cell harvest in these patients after treatment with this induction therapy regimen and in vivo purging with rituximab.
OUTLINE: This is a multicenter study.
- Remission induction: Patients receive cladribine subcutaneously (SC) on days 1-5. During courses 2-4, patients also receive rituximab IV on day 1. Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. If unacceptable toxicity persists, patients receive rituximab alone.
Patients not achieving a complete remission (CR), very good partial remission (VGPR), or nodular partial remission (NPR) receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 21 days for up to 4 courses or until patients achieve a CR, VGPR, or NPR.
Patients achieving a CR, VGPR, or NPR proceed to stem cell mobilization and in vivo purging.
- Stem cell mobilization and in vivo purging: Beginning 8-10 weeks after the first day of the last course of remission induction or CHOP, patients receive rituximab IV on days 1 and 8, cyclophosphamide IV over 4 hours on day 2, and filgrastim (G-CSF) SC daily beginning on day 4 and continuing until the last day of apheresis. Patients undergo apheresis on days 11-14.
PROJECTED ACCRUAL: A total of 17-41 patients will be accrued for this study within 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial|
|Study Start Date :||June 2002|
|Actual Primary Completion Date :||March 2003|
|Actual Study Completion Date :||October 2010|
- Biological: filgrastim
- Biological: rituximab
- Drug: CHOP regimen
- Drug: cladribine
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- Drug: prednisone
- Drug: vincristine sulfate
- Complete-remission rate after induction [ Time Frame: 30 days ]
- Very good partial remission and nodular partial remission after induction [ Time Frame: 30 days ]
- Toxicity (hematotoxicity and infection rate) at 30 days following study treatment [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00072007
|Aarau, Switzerland, 5001|
|Oncology Institute of Southern Switzerland|
|Bellinzona, Switzerland, CH-6500|
|Bern, Switzerland, CH-3010|
|Spitaeler Chur AG|
|Chur, Switzerland, CH-7000|
|Centre Hospitalier Universitaire Vaudois|
|Lausanne, Switzerland, CH-1011|
|Luzerne, Switzerland, CH-6000|
|Hopital des Cadolles, Neuchatel|
|Neuchatel, Switzerland, 2000|
|Praxis Dr. Beretta|
|Rheinfelden, Switzerland, 4310|
|Kantonsspital - St. Gallen|
|St. Gallen, Switzerland, CH-9007|
|Zurich, Switzerland, 8038|
|Zurich, Switzerland, CH-8091|
|Study Chair:||Reinhard Zenhaeusern, MD||University Hospital Inselspital, Berne|